<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495478</url>
  </required_header>
  <id_info>
    <org_study_id>17748</org_study_id>
    <secondary_id>I4T-MC-JVDT</secondary_id>
    <nct_id>NCT04495478</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab (LY3009806) in Healthy Participants</brief_title>
  <official_title>A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a new formulation of ramucirumab, a drug approved for several types of&#xD;
      cancer.&#xD;
&#xD;
      In this study of healthy participants, a small amount of ramucirumab will be given by&#xD;
      injection either into a vein or just under the skin. Study doctors will measure the amount of&#xD;
      ramucirumab in the bloodstream.&#xD;
&#xD;
      Side effects and tolerability will be documented. The study will last for about 16 weeks for&#xD;
      each participant, including screening and follow up. Screening is required within 28 days&#xD;
      prior to entering the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2020</start_date>
  <completion_date type="Actual">May 9, 2021</completion_date>
  <primary_completion_date type="Actual">May 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 90</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with an Injection Site Reaction (ISR[s])</measure>
    <time_frame>Day 1 Predose through Day 90</time_frame>
    <description>Percentage of Participants with an ISR(s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Ramucirumab</measure>
    <time_frame>Baseline through Day 90</time_frame>
    <description>PK: AUC of Ramucirumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Ramucirumab</measure>
    <time_frame>Baseline through Day 90</time_frame>
    <description>PK: Cmax of Ramucirumab</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ramucirumab - Intravenous (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramucirumab - Subcutaneous (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab - IV</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Ramucirumab - Intravenous (IV)</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Ramucirumab - Subcutaneous (SC)</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy male or a female (not pregnant and agreeable to take birth control&#xD;
             measures until study completion)&#xD;
&#xD;
          -  Have a body weight greater than or equal to (≥)70 kilograms (kg) and body mass index&#xD;
             (BMI) of 18 to 32 kilogram per square meter (kg/m ²), inclusive&#xD;
&#xD;
          -  Have normal blood pressure, pulse rate, electrocardiogram (ECG), and blood and urine&#xD;
             laboratory test results that are acceptable for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently participating in or completed a clinical trial within the last 30 days&#xD;
             or any other type of medical research judged to be incompatible with this study&#xD;
&#xD;
          -  Have previously participated or withdrawn from this study&#xD;
&#xD;
          -  Have or used to have health problems or laboratory test results or ECG readings that,&#xD;
             in the opinion of the doctor, could make it unsafe to participate, or could interfere&#xD;
             with understanding the results of the study&#xD;
&#xD;
          -  Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 16, 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramucirumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

